INNA-051 is a broad spectrum antiviral immunomodulatory nasal spray, which is under clinical development to treat pre- and post-exposure prophylaxis of respiratory viral infections in people at risk
Cariprazine is intended for the adjunctive treatment of MDD patients who are receiving ongoing antidepressant therapy. The company’s sNDA submission is based on data obtained from clinical trials
Utidelone Injection, developed by Beijing Biostar Pharmaceuticals, is a new natural microbial small-molecule anticancer drug that is a genetically engineered epothilone derivative. It is a new non- taxane
DZD4205 (Golidocitinib) is a selective JAK1 inhibitor in relapsed/refractory peripheral T-Cell lymphoma. The orally available, JAK1-specific inhibitor has showed that 21 (42.9%) out of the 49 patients have
Led by Perceptive Advisors, the financing round has seen participation from existing investors RA Capital Management, Wellington Management, and Moore Strategic Ventures. The new investors include Declaration Partners,
SBT101 is in development for compensating the disease-causing ABCD1 mutation. It is designed for reducing very long chain fatty acid (VLCFA) levels and increase ABCD1 expression for AMN
These patients have received at least one prior systemic therapy earlier. Adagrasib is an investigational, potent oral small-molecule therapy which is designed to shrink difficult-to-treat cancers that are
As per the terms of the collaboration, Adcentrx will specify the targets against which AvantGen will screen for new antibodies by making use of its yeast display system.
The acceptance by the FDA is based on the positive data from a Phase II study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
As part of the collaboration, the companies will use Nurosene’s core AI tools, NetraHealthAtlas, to speed up the drug discovery process. NetraHealthAtlas is designed to produce insights regarding
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.